| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 392,604 | 353,829 | ||
| Short-term investments | 338,465 | 328,157 | ||
| Accounts receivable, net | 129,633 | 111,439 | ||
| Inventory | 37,632 | 31,041 | ||
| Prepaid taxes | 10,103 | - | ||
| Prepaid expenses and other current assets | 17,213 | 16,881 | ||
| Total current assets | 925,650 | 841,347 | ||
| Property and equipment, net | 148,871 | 150,388 | ||
| Long-term investments | 133,113 | 138,807 | ||
| Right-of-use assets | 7,447 | 7,655 | ||
| Deferred tax asset, net of valuation allowance | 24,680 | - | ||
| Other non-current assets | 333 | 197 | ||
| Total assets | 1,240,094 | 1,138,394 | ||
| Accounts payable | 2,097 | 7,124 | ||
| Current portion of lease liability | 1,698 | 1,617 | ||
| Accrued rebates | 55,769 | 51,638 | ||
| Accrued expenses and other current liabilities | 31,704 | 26,517 | ||
| Total current liabilities | 91,268 | 86,896 | ||
| Lease liability | 7,813 | 8,064 | ||
| Other long-term liabilities | 3,137 | 2,787 | ||
| Total liabilities | 102,218 | 97,747 | ||
| Additional paid-in capital | 1,164,013 | 1,146,092 | ||
| Accumulated other comprehensive gain (loss) | 1,100 | 1,157 | ||
| Accumulated deficit | -27,237 | -106,602 | ||
| Total stockholders equity | 1,137,876 | 1,040,647 | ||
| Total liabilities and stockholders equity | 1,240,094 | 1,138,394 | ||
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)